Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Zaltenibart has shown multiple potential advantages over other alternative pathway inhibitors in development or on the market

  80% confidence

• The remaining proceeds from the closing payment will be sufficient to repay at or prior to maturity the remaining $17.1 million principal balance on its 2026 Convertible Notes and fund more than 12 months of operations, including the anticipated U.S. launch of narsoplimab for TA-TMA

  80% confidence

• Omeros is eligible to receive up to $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales

  80% confidence

• MASP-3 inhibition preserves classical pathway activity, which is critical to vaccine-induced immunity and defense against infections, unlike inhibitors of C3 or C5

  80% confidence

• Novo Nordisk is strongly positioned to develop zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders

  80% confidence

• MASP-3 is considered a highly attractive therapeutic target due to low systemic levels compared to other alternative pathway proteins and slow clearance from circulation

  80% confidence

• Omeros is eligible to receive upfront and near-term milestone payments up to $340 million

  80% confidence

• MASP-3 is not believed to be an acute-phase reactant, potentially offering another significant advantage for MASP-3 inhibitors like zaltenibart

  80% confidence